1y2m: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
New page: left|200px<br /><applet load="1y2m" size="450" color="white" frame="true" align="right" spinBox="true" caption="1y2m, resolution 1.60Å" /> '''Crystal structure of...
 
OCA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:1y2m.jpg|left|200px]]<br /><applet load="1y2m" size="450" color="white" frame="true" align="right" spinBox="true"  
[[Image:1y2m.jpg|left|200px]]<br /><applet load="1y2m" size="350" color="white" frame="true" align="right" spinBox="true"  
caption="1y2m, resolution 1.60&Aring;" />
caption="1y2m, resolution 1.60&Aring;" />
'''Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides'''<br />
'''Crystal structure of phenylalanine ammonia-lyase from yeast Rhododporidium toruloides'''<br />


==Overview==
==Overview==
Structure-based protein engineering coupled with chemical modifications, (e.g., pegylation) is a powerful combination to significantly improve the, development of proteins as therapeutic agents. As a test case, phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) was selected for enzyme, replacement therapy in phenylketonuria [C.R. Scriver, S. Kaufman, Hyperphenylalaninemia:phenylalanine Hydroxylase Deficiency. The Metabolic, and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 2001, Chapter 77], an inherited metabolic disorder (OMIM 261600) causing mental, retardation due to deficiency of the enzyme l-phenylalanine hydroxylase, (EC 1.14.16.1). Previous in vivo studies of recombinant PAL demonstrated a, lowering of blood l-phenylalanine levels; yet, the metabolic effect was, not sustained due to protein degradation and immunogenicity [C.N., Sarkissian, Z. Shao, F. Blain, R. Peevers, H. Su, R. Heft, T.M. Chang, C.R. Scriver, A different approach to treatment of, phenylketonuria:phenylalanine degradation with recombinant phenylalanine, ammonia lyase, Proc. Natl. Acad. Sci. USA 96 (1999) 2339; J.A. Hoskins, G., Jack, H.E. Wade, R.J. Peiris, E.C. Wright, D.J. Starr, J. Stern, Enzymatic, control of phenylalanine intake in phenylketonuria, Lancet 1 (1980) 392;, C.M. Ambrus, S. Anthone, C. Horvath, K. Kalghatgi, A.S. Lele, G. Eapen, J.L. Ambrus, A.J. Ryan, P. Li, Extracorporeal enzyme reactors for, depletion of phenylalanine in phenylketonuria, Ann. Intern. Med. 106, (1987) 531]. Here, we report the 1.6A three-dimensional structure of, Rhodosporidium toruloides PAL, structure-based molecular engineering, pegylation of PAL, as well as in vitro and in vivo PKU mouse model studies, on pegylated PAL formulations. Our results show that pegylation of R., toruloides PAL leads to promising therapeutic efficacy after subcutaneous, injection by enhancing the in vivo activity, lowering plasma, phenylalanine, and leading to reduced immunogenicity. The, three-dimensional structure of PAL provides a basis for understanding the, properties of pegylated forms of PAL and strategies for structure-based, re-engineering of PAL for PKU treatment.
Structure-based protein engineering coupled with chemical modifications (e.g., pegylation) is a powerful combination to significantly improve the development of proteins as therapeutic agents. As a test case, phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) was selected for enzyme replacement therapy in phenylketonuria [C.R. Scriver, S. Kaufman, Hyperphenylalaninemia:phenylalanine Hydroxylase Deficiency. The Metabolic and Molecular Bases of Inherited Disease, McGraw-Hill, New York, 2001, Chapter 77], an inherited metabolic disorder (OMIM 261600) causing mental retardation due to deficiency of the enzyme l-phenylalanine hydroxylase (EC 1.14.16.1). Previous in vivo studies of recombinant PAL demonstrated a lowering of blood l-phenylalanine levels; yet, the metabolic effect was not sustained due to protein degradation and immunogenicity [C.N. Sarkissian, Z. Shao, F. Blain, R. Peevers, H. Su, R. Heft, T.M. Chang, C.R. Scriver, A different approach to treatment of phenylketonuria:phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA 96 (1999) 2339; J.A. Hoskins, G. Jack, H.E. Wade, R.J. Peiris, E.C. Wright, D.J. Starr, J. Stern, Enzymatic control of phenylalanine intake in phenylketonuria, Lancet 1 (1980) 392; C.M. Ambrus, S. Anthone, C. Horvath, K. Kalghatgi, A.S. Lele, G. Eapen, J.L. Ambrus, A.J. Ryan, P. Li, Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria, Ann. Intern. Med. 106 (1987) 531]. Here, we report the 1.6A three-dimensional structure of Rhodosporidium toruloides PAL, structure-based molecular engineering, pegylation of PAL, as well as in vitro and in vivo PKU mouse model studies on pegylated PAL formulations. Our results show that pegylation of R. toruloides PAL leads to promising therapeutic efficacy after subcutaneous injection by enhancing the in vivo activity, lowering plasma phenylalanine, and leading to reduced immunogenicity. The three-dimensional structure of PAL provides a basis for understanding the properties of pegylated forms of PAL and strategies for structure-based re-engineering of PAL for PKU treatment.


==About this Structure==
==About this Structure==
1Y2M is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rhodosporidium_toruloides Rhodosporidium toruloides]. Active as [http://en.wikipedia.org/wiki/Phenylalanine_ammonia-lyase Phenylalanine ammonia-lyase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.3.1.5 4.3.1.5] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1Y2M OCA].  
1Y2M is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Rhodosporidium_toruloides Rhodosporidium toruloides]. Active as [http://en.wikipedia.org/wiki/Phenylalanine_ammonia-lyase Phenylalanine ammonia-lyase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.3.1.5 4.3.1.5] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1Y2M OCA].  


==Reference==
==Reference==
Line 15: Line 15:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Gamez, A.]]
[[Category: Gamez, A.]]
[[Category: Han, G.W.]]
[[Category: Han, G W.]]
[[Category: Patch, M.G.]]
[[Category: Patch, M G.]]
[[Category: Sarkissian, C.N.]]
[[Category: Sarkissian, C N.]]
[[Category: Scriver, C.R.]]
[[Category: Scriver, C R.]]
[[Category: Stevens, R.C.]]
[[Category: Stevens, R C.]]
[[Category: Straub, M.]]
[[Category: Straub, M.]]
[[Category: Wang, L.]]
[[Category: Wang, L.]]
[[Category: alpha helices]]
[[Category: alpha helices]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Wed Nov 21 06:31:13 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:01:12 2008''